What tirzepatide is
Tirzepatide is a once-weekly injectable that activates two gut-hormone receptors at once: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both hormones are released from the intestine after you eat; the medication “activates receptors of hormones secreted from the intestine … to reduce appetite and food intake,” in the FDA’s words (FDA approval announcement, Nov 8 2023).
Semaglutide acts on the GLP-1 receptor only. That single-versus-dual difference is the whole reason the two medications get compared — and why they are not interchangeable.
The brand products are Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), the latter approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol (same source).
What the trials show
The pivotal obesity trial (SURMOUNT-1). 2,539 adults with obesity, 72 weeks. Mean weight change: −15.0% at 5 mg, −19.5% at 10 mg, −20.9% at 15 mg, versus −3.1% on placebo. At the two higher doses, 50–57% of participants lost at least 20% of their body weight, versus 3% on placebo (Jastreboff et al., NEJM 2022).
Head-to-head with semaglutide (SURMOUNT-5). The first direct comparison in adults with obesity: tirzepatide −20.2% versus semaglutide −13.7% at 72 weeks, with a larger waist-circumference reduction (−18.4 cm vs −13.0 cm) and more participants reaching each weight-loss threshold (Aronne et al., NEJM 2025).
Two honest caveats. First, these are trial populations on brand-name product with structured lifestyle support; real-world results vary. Second, “more weight loss” is not automatically “better for you” — the right medication depends on your history, your tolerance for side effects, and your goals, which is what the provider evaluation is for.
Side effects, plainly
The common ones are gastrointestinal — nausea, diarrhea, vomiting, constipation, abdominal discomfort — plus injection-site reactions and fatigue (FDA). In SURMOUNT-1 they were “mostly mild to moderate,” occurred mainly during dose escalation, and 4.3–7.1% of participants stopped because of them (Jastreboff 2022). Slow, scheduled dose increases are how providers manage this; our guide to managing GLP-1 side effects covers the practical side.
The serious warnings are the same class warnings that apply to semaglutide: the label carries a boxed warning because tirzepatide “causes thyroid C-cell tumors in rats,” and it is not used in people with a personal or family history of medullary thyroid carcinoma or MEN 2, or with a history of pancreatitis or severe gastrointestinal disease (FDA, same source). Your provider screens for all of these before prescribing.
Because faster weight loss can mean more lean-mass loss, protein intake and resistance training matter more on tirzepatide, not less — see GLP-1 and muscle preservation.
Compounding status in 2026
This is where tirzepatide differs most from semaglutide practically. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024; the enforcement-discretion window for 503A compounding pharmacies ended February 18, 2025 (outsourcing facilities, March 19, 2025) (FDA — compounding policy update, last updated Apr 1 2026).
After a shortage ends, the law reverts to its normal shape. A compounded drug must be made “for an individual patient based on receipt of a prescription,” and pharmacies may not compound “regularly or in inordinate amounts” products that are “essentially copies of a commercially available drug product” — unless a prescriber “determines and documents the compounded drug product contains a change that produces a significant difference … for an identified individual patient” (same source).
In plain terms: mass-produced “copycat” tirzepatide is over. Patient-specific compounding remains lawful when a provider documents a clinical reason for a different formulation. That is a provider’s determination, made for you, not a checkbox. Our plain-language guides to compounded semaglutide in 2026 and compounded vs. brand-name medications walk through the same framework.
How BioPeakRx handles it
Tirzepatide is available only after a licensed provider evaluates you — history, goals, contraindications, and whether a compounded formulation is clinically appropriate and documented for you. It is prepared by a US, FDA-registered compounding pharmacy on that prescription, and billed as a monthly, cancel-anytime subscription with the price and renewal terms shown before you pay. The therapy page and pricing are at /treatments/tirzepatide/; the side-by-side with semaglutide is here.
Compounded medications are not FDA-approved. This article is education, not medical advice, and does not establish a provider–patient relationship.
Sources: FDA — Zepbound approval, Nov 8 2023 · Jastreboff AM et al., N Engl J Med 2022 — SURMOUNT-1 (PMID 35658024) · Aronne LJ et al., N Engl J Med 2025 — SURMOUNT-5 (PMID 40353578) · FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated Apr 1 2026)